Weight-loss drugs cut alcohol intake by almost two-thirds, research in Ireland suggests

Patients describe the reduction, which occurred in just four months, as effortless

2025-05-09

(Press-News.org) Individuals who take liraglutide or semaglutide for weight loss reduce their alcohol consumption by almost two-thirds in four months, new research being presented at this year’s European Congress on Obesity (ECO 2025) has found.

Alcohol use disorder is a relapsing condition that accounts for 2.6 million deaths a year – 4.7% of all deaths globally.

Treatments such as cognitive behavioural therapy (CBT), therapies that aim to strengthen motivation to stop or reduce drinking and medication can be very successful in the short-term, however, 70% of patients relapse within the first year.

Glucagon-like peptide-1 (GLP-1) analogues, drugs developed to treat obesity, have reduced alcohol intake in animal studies, but reports are only starting to emerge about their effect on alcohol intake in humans.

To find out more, Professor Carel le Roux, of University College Dublin, and colleagues in Ireland and Saudi Arabia prospectively collected data on the alcohol intake of patients who were being treated for obesity at a clinic in Dublin.

The real-world study involved 262 adults with a BMI ≥27 kg/m² (79% female, average age 46 years, average weight 98kg/15 stone 6lb) who were prescribed the GLP-1 analogues liraglutide or semaglutide for weight loss.

The patients were categorised into non-drinkers (n=31, 11.8%) rare drinkers (<10 units/week, n=52 19.8%) and regular drinkers (>10 units/week, n=179, 68.4%) based on their self-reported alcohol intake before they started taking the weight-loss drugs.

188 of the 262 patients were followed-up for an average 4 of months. None of them had increased their alcohol intake.

Average alcohol intake decreased from 11.3 units/week to 4.3 units/week after 4 months of treatment with the GLP-1 analogues – a reduction of almost two-thirds.

Among the regular drinkers, intake decreased from 23.2 units/week to 7.8 units/week. This reduction of 68% is comparable to that achieved by nalmefene, a drug used to treat alcohol use disorder in Europe, notes Professor le Roux.

He adds: “The exact mechanism of how GLP-1 analogues reduce alcohol intake is still being investigated but it is thought to involve curbing cravings for alcohol that arise in subcortical areas of the brain that are not under conscious control. Thus, patients report the effects are ‘effortless’.”

The study’s limitations include the relatively small number of patients, the use of self-reported alcohol intake and the absence of a control group. Its strengths include the use of data collected prospectively in a real-world setting.

Professor Le Roux concludes: “GLP-1 analogues have been shown treat obesity and reduce the risk of multiple obesity-related complications. Now, the beneficial effects beyond obesity, such as on alcohol intake, are being actively studied, with some promising results.”

Professor Carel Le Roux, Diabetes Complications Research Centre, University College Dublin, Ireland. T) +353 864 117 842 E) carel.leroux@nmh.ie

Tony Kirby in the ECO Media Centre. T) +44 7834 385827 E) tony.kirby@tonykirby.com

Notes to editors:

Dr Faisal I. Almohaileb reports no competing interests. Dr Maurice O'Farrell provides obesity clinical care in the Medication Weight Loss Clinic and is the owner of this clinic. M.O'.F has served on advisory boards for Novo Nordisk and Johnson & Johnson, both positions unremunerated. Prof Carel le Roux (C.l.R) reports grants from the EU Innovative Medicine Initiative, Irish Research Council, Science Foundation Ireland, Anabio, and the Health Research Board. He serves on advisory boards and speakers panels of Novo Nordisk, Roche, Herbalife, GI Dynamics, Eli Lilly, Johnson & Johnson, Gila, Irish Life Health, Boehringer Ingelheim, Currax, Zealand Pharma, Keyron, AstraZeneca, Arrowhead Pharma, Amgen, and Rhythm Pharma. C.l.R is the Chair of the Irish Society for Nutrition and Metabolism. C.l.R provides obesity clinical care in the My Best Weight clinic and Beyond BMI clinic and is a shareholder.

This press release is based on poster abstract 1291 at the European Congress on Obesity (ECO) in Malaga, Spain, 11-14 May. The material has been peer reviewed by the congress selection committee. As the full paper is provided, the abstract is not provided.

The study has been published in the journal Diabetes, Obesity and Metabolism. For link to full study, click here

For link you can use in your stories, click here

For poster click here

END

ELSE PRESS RELEASES FROM THIS DATE:

Swedish study explores differences in how the sexes break down fat

2025-05-09

The research focused on lipolysis, the process through which triglycerides – lipids stored in fat cells – are broken down to produce free fatty acids and glycerol, which can be used as energy, during exercise or between meals. “The breakdown of lipids through lipolysis is essential for energy balance and it is believed that doing it effectively may prevent type 2 diabetes and other metabolic complications of overweight and obesity,” says Professor Peter Arner, of the Karolinska Institutet, Stockholm, ...

Antibiotics taken during infancy linked to early puberty in girls

2025-05-09

Girls given antibiotics during their first year of life, especially in the first three months, are more likely to enter puberty at an earlier age, according to research presented at the first Joint Congress between the European Society of Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE). The likelihood of early puberty was also higher among those exposed to a greater variety of antibiotic classes. The findings highlight the importance of using these medicines in infants appropriately ...

Real-world evidence links long-term use of oral and inhaled steroids to adrenal insufficiency

2025-05-09

Individuals taking steroid tablets for more than 3 months are over 6 times more likely to be diagnosed with adrenal insufficiency than those treated with non-steroidal anti-inflammatory drugs, according to research presented at the first Joint Congress between the European Society of Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE). In addition, they have a greater risk of being hospitalised for adrenal insufficiency, while long-term users of inhaled steroids have an increased risk of developing adrenal insufficiency but without any increase in the number of hospitalisations. The findings ...

Phthalates may impact key genital measurement in 3-year-olds

2025-05-09

Three-year-old boys are more likely to have a shorter anogenital distance when their mothers have high levels of phthalates in their urine, according to research presented at the first Joint Congress between the European Society of Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE). In girls, the direct exposure to phthalates was associated with a shorter anogenital distance. The findings highlight how exposure to environmental pollutants can cause alterations in genital measurements during the first three years of life, which may affect sexual development and fertility later in life. Phthalates ...

Phosphate levels in blood strongly affect sperm quality in men

2025-05-09

Men with fertility issues have lower levels of phosphate in the blood than average, according to research presented at the first Joint Congress between the European Society of Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE). In addition, low phosphate concentrations in the blood were associated with reduced sperm motility in infertile men. The findings can help researchers improve the understanding of the biological factors involved in male reproductive health, which could lead to new fertility treatments. Over the past 50 years, sperm counts worldwide have halved, sperm quality has declined alarmingly and 15% of all heterosexual couples are ...

Testosterone during pregnancy linked to physical activity and muscle strength in children

2025-05-09

Boys born to mothers who have polycystic ovary syndrome (PCOS) or who have higher levels of testosterone during the third trimester are more likely to be less physically active at age 7, according to research presented at the first Joint Congress between the European Society of Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE). Testosterone levels or PCOS in the mothers were not associated with physical activity in girls, but 7-year-old girls whose mothers had higher testosterone levels during pregnancy had lower muscle strength. The findings highlight the important role that maternal testosterone and PCOS may play in future development in boys and girls ...

Menopause at an earlier age increases risk of fatty liver disease and metabolic disorders

2025-05-09

Women who experience menopause before the age of 50 — and especially before the age of 45 — are more likely to develop fatty liver disease and its related metabolic risk factors within one year after menopause, according to research presented at the first Joint Congress between the European Society of Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE). This study is the largest to assess this association over five years and suggests that the age of natural menopause should be considered part of the cardio-metabolic risk assessment ...

Early-life growth proved important for height in puberty and adulthood

2025-05-09

Growth patterns during the first two years of a child’s life may shape pubertal growth and adult height, but have little effect on pubertal timing, according to research presented at the first Joint Congress between the European Society of Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE). The findings highlight the importance of early-life growth, which could be used as a marker to predict future growth, development and health. It is well established that the early-life growth period — from conception to approximately two years of age — is crucial ...

Women with infertility history at greater risk of cardiovascular disease after assisted conception

2025-05-09

Women who experience infertility are more likely to develop heart and blood vessel conditions later in life, with younger women and those who undergo fertility treatments at a greater risk. The findings, presented at the first Joint Congress between the European Society of Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE), highlight the importance of considering a woman’s reproductive history when assessing her long-term heart health. Approximately one in every six people of reproductive age worldwide is estimated to experience infertility in their lifetime. Treatment of infertility ...

UO researcher develops new tool that could aid drug development

2025-05-09

Computer simulations help materials scientists and biochemists study the motion of macromolecules, advancing the development of new drugs and sustainable materials. However, these simulations pose a challenge for even the most powerful supercomputers. A University of Oregon graduate student has developed a new mathematical equation that significantly improves the accuracy of the simplified computer models used to study the motion and behavior of large molecules such as proteins, nucleic acids and synthetic materials such as plastics. The breakthrough, published last month in Physical Review Letters, enhances researchers’ ability to investigate the motion ...

Weight-loss drugs cut alcohol intake by almost two-thirds, research in Ireland suggests

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: